Nobel 2017 season opens with medicine prize

Agencies
October 2, 2017

Stockholm, Oct 2: This year's Nobel season opens Monday with the announcement of the medicine prize, turning the page on Bob Dylan's literature prize stunner that stole the spotlight in last year's award season.

Like every year, speculation is rife about the possible winners, given the number of worthy laureates in the fields of medicine, physics, chemistry, literature, peace and economics.

The Nobel medicine prize committee at the Karolinska Institute is first out to announce its choice of laureates, on Monday at 11:30 am (0930 GMT) at the earliest.

Sweden's newspaper of reference, Dagens Nyheter, suggested American oncologist Dennis Slamon could be honoured for his research on breast cancer and the drug treatment Herceptin.

Or possibly American James Allison, a pioneer in the field of immunotherapy that combats cancer cells and the winner of the 2015 Lasker Prize -- often considered the US equivalent of a Nobel medicine prize. If this method were awarded, Allison could share the prize with Arlene Sharpe and Gordon Freeman.

Meanwhile Swedish public radio SR tipped the prize could go to researchers who worked on a cure for Hepatitis C, Ralf Bartenschlager of Germany and Americans Charles Rice and Michael Sofia -- a trio also awarded the Lasker Prize, in 2016.

Waves, scissors or batteries?

The medicine prize will be followed by the physics prize announcement on Tuesday, with the discovery of gravitational waves regularly mentioned as a possible winner.

Sending ripples through space and time, gravitational waves were first predicted by Albert Einstein a century ago as part of his theory of general relativity, but the first hard evidence of their existence came only in 2015, when two US detectors found the first such signal.

That discovery could however be considered too recent by the Nobel committee.

According to Dagens Nyheter, the jury could instead choose to honour the discovery of exoplanets by Swiss astrophysicians Michel Mayor and Didier Queloz.

On Wednesday, the chemistry prize committee could give the nod to a gene-editing technique known as the CRISPR-Cas9 DNA snipping tool, a type of genetic "scissors" used to cut out a mutated gene in a human embryo and replace it by a corrected version.

But that discovery could also be too early for a Nobel, as a legal dispute rages over who discovered the technique.

It has been claimed on the one hand by the French-American research duo of Emmanuelle Charpentier and Jennifer Doudna, and on the other by Chinese-born American Feng Zhang.

Another recurring favourite for the chemistry prize is John Goodenough, a 95-year old electrochemist whose pioneering work led to the invention of rechargeable lithium ion battery present in cell phones, computers and electric cars.

Anti-nuke buzz for peace prize

Perhaps the most watched Nobel is the peace prize, the only one to be announced in Oslo and due on Friday.

This year, anti-nuclear efforts could win, some have suggested. Tensions have escalated between Washington and Pyongyang after North Korea's sixth nuclear test, and there is growing uncertainty over the Iran deal, which US President Donald Trump has threatened to tear up.

Two key orchestrators of that accord, Iranian Foreign Minister Mohammad Javad Zarif and EU foreign policy chief Federica Mogherini, are seen as strong contenders by the head of the Peace Research Institute of Oslo (Prio), Henrik Urdal.

"With North Korea also at stake, it's very important to support initiatives that guard against the development and proliferation of nuclear weapons," he said.

The names of the candidates are kept secret for at least 50 years, but those eligible to nominate candidates — including former laureates, lawmakers and government ministers around the world, and some university professors — are allowed to disclose their choices.

Those believed to be on the list include Syria's White Helmets rescue service, Congolese doctor Denis Mukwege, jailed Saudi blogger Raif Badawi and Edward Snowden, who revealed the scope of America's NSA electronic surveillance programme.

Meanwhile, the Swedish Academy has yet to set the date for its literature prize announcement, but it traditionally falls on a Thursday so October 5 and 12 are seen as possible dates.

The Academy's choice of US singer songwriter Bob Dylan last year was so divisive that Stockholm's literary circles have predicted the Academy will go for a more conservative name this year, such as Italy's Claudio Magris, Kenya's Ngugi wa Thiong'o, Canadian author Margaret Atwood or Syrian poet Adonis.

The economics prize will be announced on October 9.

This year, each Nobel comes with a nine million kronor ($1.1-million, 940,500-euro) prize sum, to be shared if several laureates are honoured in the same discipline.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 6,2020

Singapore, May 6: Oil prices slipped back Wednesday after two days of gains, although Brent crude remained above $30 a barrel, as renewed US-China tensions offset optimism about the easing of coronavirus lockdowns.

Brent, the international benchmark, fell 1.1 per cent to $30.63 a barrel in early Asian trade. On Tuesday, the contract surged 14 per cent and rose above $30 for the first time since mid-April.

US marker West Texas Intermediate slipped 1.9 per cent and was changing hands for $24.13 a barrel.

Oil markets have been battered as the virus strangled demand due to business closures and travel restrictions, with US crude falling into negative territory last month for the first time.

They started rallying strongly this week as countries from Europe to Asia ease curbs and economies start shuddering back to life.

But gains were capped Wednesday as dealers follow a brewing US-China row after Donald Trump hit out at Beijing over its handling of the outbreak, saying it began in a Wuhan lab, but so far offering no evidence.

"Traders are incredibly cautious this morning, weighing all the possible China responses," said Stephen Innes, chief global market strategist at AxiCorp.

"And the one that would hurt the most would be for China to reduce imports of US oil."

This week's rally was in part driven by a deal agreed between top producers to reduce output by almost 10 million barrels a day, which came into effect on May 1.

There have also been signs that the massive oversupply in the market is starting to ease as demand slowly comes back.

Energy data provider Genscape said earlier this week that stockpiles at the main US oil depot in Cushing, Oklahoma had increased by only 1.8 million barrels last week following weeks of major rises.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 24,2020

Toronto, Apr 25: Canadian Prime Minister Justin Trudeau on Thursday (local time) announced a new CAD 1.1 billion package supporting vaccine research and clinical trials as well as expanded testing capacity.

"We are putting in place an additional CAD 1.1 billion dollars for a national medical and research strategy to address COVID-19," Trudeau said during his daily novel coronavirus pandemic briefing on Thursday.

"This plan has three pillars -- research on vaccines and other treatments, support for clinical trials and expanding national testing and modelling," he added.

Trudeau pointed out that CAD 82 million of the total sum will be directed to the development of a vaccine and treatments against the virus, while CAD 471 million will go towards supporting clinical trials.

A further CAD 249 million is being allocated for expanding testing capacity and modelling, the Prime Minister added.

According to Trudeau, this funding will be allotted to a new "immunity task force" commissioned with conducting serology testing -- blood tests looking for the presence of antibodies indicative of exposure to the virus and subsequent immune response.

He said the taskforce, comprising the country's top medical experts, including Chief Public Health Officer Dr Theresa Tam, will test at least a million Canadians over the next two years.

The funding announced today comes in addition to the CAD 200 million committed for COVID-19-related research on March 11.

Trudeau has repeatedly stressed the daily constraints that much of the population is adhering to will be the new normal until a vaccine is developed.

As of Thursday, Canada has confirmed a total of 40,824 COVID-19 cases since the onset of the outbreak, out of which more than 2,000 have proven to be fatal, according to the latest figures from the country's public health agency.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 10,2020

Melbourne, Apr 10: Scientists have identified six drug candidates from more than 10,000 compounds that may help treat COVID-19.

The research, published in the journal Nature, tested the efficacy of approved drugs, drug candidates in clinical trials and other compounds.

"Currently there are no targeted therapeutics or effective treatment options for COVID-19," said Professor Luke Guddat from the University of Queensland in Australia.

"In order to rapidly discover lead compounds for clinical use, we initiated a programme of high-throughput drug screening, both in laboratories and also using the latest computer software to predict how different drugs bind to the virus," Guddat said.

The project targeted the main COVID-19 virus enzyme, known as the main protease or Mpro, which plays a pivotal role in mediating viral replication, the researchers said.

This makes it an attractive drug target for this virus, and as people don't naturally have this enzyme, compounds that target it are likely to have low toxicity, they said.

"We add the drugs directly to the enzyme or to cell cultures growing the virus and assess how much of each compound is required to stop the enzyme from working or to kill the virus. If the amount is small, then we have a promising compound for further studies," said Guddat.

After assaying thousands of drugs, researchers found of the six that appear to be effective in inhibiting the enzyme, one is of particular interest.

"We're particularly looking at several leads that have been subjected to clinical trials including for the prevention and treatment of various disorders such as cardiovascular diseases, arthritis, stroke, atherosclerosis and cancer," Guddat said.

Researchers said compounds that are already along the pipeline to drug discovery are preferred, as they can be further tested as antivirals at an accelerated rate compared to new drug leads that would have to go through this process from scratch.

"With continued and up-scaled efforts we are optimistic that new candidates can enter the COVID-19 drug discovery pipeline in the near future," Guddat said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.